Nanjing Vishee Medical Technology Future Growth
Future criteria checks 5/6
Nanjing Vishee Medical Technology is forecast to grow earnings and revenue by 29.7% and 25% per annum respectively. EPS is expected to grow by 29.5% per annum. Return on equity is forecast to be 11.7% in 3 years.
Key information
29.7%
Earnings growth rate
29.5%
EPS growth rate
Medical Equipment earnings growth | 25.7% |
Revenue growth rate | 25.0% |
Future return on equity | 11.7% |
Analyst coverage | Low |
Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Nanjing Vishee Medical Technology (SHSE:688580) Will Want To Turn Around Its Return Trends
Dec 17Earnings Troubles May Signal Larger Issues for Nanjing Vishee Medical Technology (SHSE:688580) Shareholders
Nov 01Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Shares Leap 35% Yet They're Still Not Telling The Full Story
Oct 07Nanjing Vishee Medical Technology (SHSE:688580) Is Reinvesting At Lower Rates Of Return
Aug 23Investors Don't See Light At End Of Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Tunnel
Jun 06Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)
May 02Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Shares Fly 30% But Investors Aren't Buying For Growth
Mar 06Nanjing Vishee Medical Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 770 | 237 | N/A | 247 | 3 |
12/31/2025 | 612 | 187 | N/A | 200 | 4 |
12/31/2024 | 505 | 150 | N/A | 137 | 4 |
9/30/2024 | 422 | 113 | -2 | 124 | N/A |
6/30/2024 | 434 | 115 | -4 | 125 | N/A |
3/31/2024 | 454 | 128 | -28 | 132 | N/A |
12/31/2023 | 462 | 136 | 1 | 134 | N/A |
9/30/2023 | 437 | 133 | -15 | 143 | N/A |
6/30/2023 | 407 | 126 | -15 | 126 | N/A |
3/31/2023 | 363 | 107 | -2 | 101 | N/A |
12/31/2022 | 322 | 94 | -9 | 86 | N/A |
9/30/2022 | 343 | 132 | 41 | 87 | N/A |
6/30/2022 | 373 | 147 | 50 | 116 | N/A |
3/31/2022 | 404 | 164 | 52 | 147 | N/A |
12/31/2021 | 430 | 178 | 70 | 157 | N/A |
9/30/2021 | 427 | 166 | 70 | 154 | N/A |
6/30/2021 | 413 | 159 | 106 | 153 | N/A |
3/31/2021 | 402 | 158 | 147 | 157 | N/A |
12/31/2020 | 378 | 144 | 109 | 121 | N/A |
9/30/2020 | 349 | 115 | 108 | 123 | N/A |
6/30/2020 | 336 | 111 | 106 | 124 | N/A |
3/31/2020 | 317 | 99 | 79 | 105 | N/A |
12/31/2019 | 319 | 100 | 120 | 141 | N/A |
12/31/2018 | 208 | 63 | 45 | 86 | N/A |
12/31/2017 | 144 | 40 | N/A | 52 | N/A |
6/30/2016 | 89 | 31 | N/A | 22 | N/A |
3/31/2016 | 85 | 29 | N/A | 24 | N/A |
12/31/2015 | 81 | 28 | N/A | 25 | N/A |
12/31/2014 | 58 | 22 | N/A | 15 | N/A |
12/31/2013 | 49 | 14 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688580's forecast earnings growth (29.7% per year) is above the savings rate (2.8%).
Earnings vs Market: 688580's earnings (29.7% per year) are forecast to grow faster than the CN market (25.5% per year).
High Growth Earnings: 688580's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688580's revenue (25% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 688580's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688580's Return on Equity is forecast to be low in 3 years time (11.7%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 04:16 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing Vishee Medical Technology Co., Ltd is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Xipeng Feng | China International Capital Corporation Limited |
Yanyin Zhu | China International Capital Corporation Limited |
Xiao Wei Lin | Everbright Securities Co. Ltd. |